TY - JOUR
T1 - Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases
AU - Thio, Quirina C.B.S.
AU - Goudriaan, W. Alexander
AU - Janssen, Stein J.
AU - Paulino Pereira, Nuno Rui
AU - Sciubba, Daniel M.
AU - Rosovksy, Rachel P.
AU - Schwab, Joseph H.
N1 - Funding Information:
Competing interests: Dr. D.M.S. is a consultant for Medtronic, Depuy-Synthes, Stryker, Nuvasive, Baxter. Dr. R.P.R. is a consultant for Bayer and has received funding from Bristol44, Meyer Squibb, Janssen Pharmaceutics, and Daiichi Sankyo. Dr. J.H.S. is a consultant for Medtronic and a speaker for Stryker and AO Spine. The other authors declare no competing interests.
Publisher Copyright:
© 2018, Cancer Research UK.
PY - 2018/9/11
Y1 - 2018/9/11
N2 - Background: Skeletal metastases are a common problem in patients with cancer, and surgical decision making depends on multiple factors including life expectancy. Identification of new prognostic factors can improve survival estimation and guide healthcare providers in surgical decision making. In this study, we aim to determine the prognostic value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with bone metastasis. Methods: One thousand and twelve patients from two tertiary referral centers between 2002 and 2014 met the inclusion criteria. Bivariate and multivariate Cox regression analyses were performed to determine the association of NLR and PLR with survival. Results: At 3 months, 84.0% of the patients with low NLR were alive versus 61.3% of the patients with a high NLR (p < 0.001), and 75.8% of the patients with a low PLR were alive versus 55.6% of the patients with a high PLR (p < 0.001). Both elevated NLR and elevated PLR were independently associated with worse survival (hazard ratio (HR): 1.311; 95% confidence interval (CI): 1.117–1.538; p = 0.001) and (HR: 1.358; 95% CI: 1.152–1.601; p < 0.001), respectively. Conclusion: This study showed both NLR and PLR to be independently associated with survival in patients who were treated for skeletal metastasis.
AB - Background: Skeletal metastases are a common problem in patients with cancer, and surgical decision making depends on multiple factors including life expectancy. Identification of new prognostic factors can improve survival estimation and guide healthcare providers in surgical decision making. In this study, we aim to determine the prognostic value of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with bone metastasis. Methods: One thousand and twelve patients from two tertiary referral centers between 2002 and 2014 met the inclusion criteria. Bivariate and multivariate Cox regression analyses were performed to determine the association of NLR and PLR with survival. Results: At 3 months, 84.0% of the patients with low NLR were alive versus 61.3% of the patients with a high NLR (p < 0.001), and 75.8% of the patients with a low PLR were alive versus 55.6% of the patients with a high PLR (p < 0.001). Both elevated NLR and elevated PLR were independently associated with worse survival (hazard ratio (HR): 1.311; 95% confidence interval (CI): 1.117–1.538; p = 0.001) and (HR: 1.358; 95% CI: 1.152–1.601; p < 0.001), respectively. Conclusion: This study showed both NLR and PLR to be independently associated with survival in patients who were treated for skeletal metastasis.
UR - http://www.scopus.com/inward/record.url?scp=85052290317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052290317&partnerID=8YFLogxK
U2 - 10.1038/s41416-018-0231-6
DO - 10.1038/s41416-018-0231-6
M3 - Article
C2 - 30116026
AN - SCOPUS:85052290317
VL - 119
SP - 737
EP - 743
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 6
ER -